What can we make of the UNVC/AGRiMED/SATIVEO combi

What can we make of the UNVC/AGRiMED/SATIVEO combination, and will the group of companies succeed? What is their goal(s)? What will become of UNVC when the cannabis transdermal patch is produced?

Medical marijuana contains antispasmodic qualities which relax muscles and has shown to be an effective treatment for seizures. Marijuana oils that are rich in cannabidol (CBD), are the preferred method for treatment. The active component of the marijuana plant, cannabinoids, have shown to inhibit tumor growth and kill cancer cells in lab testings.’ Patients who suffer from chronic pain caused by diabetes, cancer, MS, HIV, and other diseases have been turning to medical marijuana as a way to treat their pain without the use of addictive pharmaceutical medications. Research is limited but studies of the endocannabinoid system suggest benefits may include neuroprotection in MS, epilepsy, other movement disorders, and benefit in a number of mood and anxiety disorders.

Among the benefits are increased creativity, improved athletic performance, enhanced spiritual practice etc. As well it may be a safer alternative to alcohol. Cannabis affects people differently; it depends on the strain, the situation or the method of use. Further benefits are seen in immune function, neuroplasticity, emotional and mood regulation, vascular health and digestive function.

“Wherever the art of Medicine is loved, there is also a love of Humanity.” – Hippocrates.

AGRiMED has an experienced partner, with over 2.5 million square feet of grow space in several non-U.S. countries. Their proven track record in the management of commercial facilities will aid AGRiMED to optimize the site and floor plan, select appropriate technologies that work best together, include technologies that can integrate into one solution, and quickly take the initial concept to final market and sale of the medical marijuana product.

This is the promise of the UNVC/AGRiMED/SATIVEO team. While we do not know if UNVC will become more than a partner with AGRiMED/SATIVEO, we do know they are all working together to bring products to market. One must assume Doctor David Dalton was appointed to the AGRiMED Board of Directors for a reason (this is unheard of for a CEO of a sub-penny none reporting pink sheet company), and subsequently promoted to Vice Chair of that same Board. Thus, Dalton’s value must be realized by AGRiMED’s management.

Could a reverse merger be in the offing for these companies? Well, it happened recently with GTI and a non-reporting pink sheet company in Canada. Both Sterling Crockett and Bruce Goldman were founders and managers at GTI, and they left that company to found AGRiMED and latter SATIVEO. Sterling Crockett sought David Dalton out and tested UNVC’s transdermal patch before announcing their partnership. AGRiMED’s management claimed the UNVC transdermal patch performed better than the competition when asked by shareholders. So, this could be a marriage made in heaven, and the timing could not be better.